Integer (ITGR) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
19 Feb, 2026Executive summary
Achieved 8% reported and 6% organic sales growth for 2025, with adjusted operating income up 13% and adjusted EPS up 21% year-over-year, reaching the high end of guidance ranges.
2026 outlook anticipates reported sales between down 1% and up 1%, with organic sales flat to up 3%, impacted by lower adoption of three new products; underlying business, excluding these products, expected to grow 4%-6%.
Disciplined growth strategy, robust new product pipeline, and focus on strategic initiatives expected to drive above-market performance and a return to 200bps above-market organic growth in 2027.
Initiated a $50 million accelerated share repurchase program, reflecting confidence in strategy and financial position.
Financial highlights
Q4 2025 sales reached $472 million, up 5% year-over-year; full-year 2025 sales totaled $1.85 billion, up 8%.
Adjusted operating income rose 10% in Q4 and 13% for 2025; adjusted net income was $226 million, up 23%, and adjusted EPS was $6.40, up 21%.
Adjusted EBITDA for 2025 was $402 million, up 12%; free cash flow for 2025 was $105 million; capital expenditures were $91 million.
Repurchased approximately 0.7 million shares for $50 million in 2025.
Net total debt at year-end 2025 was $1.19 billion, with a leverage ratio of 3x trailing four-quarter adjusted EBITDA.
Outlook and guidance
2026 reported sales expected between $1.826 billion and $1.88 billion, down 1% to up 1%; organic sales flat to up 3%.
Excluding select new product headwinds, organic sales growth expected at 4% to 6%.
Adjusted EBITDA guidance: $391 million-$415 million (down 3% to up 3%); adjusted operating income: $304 million-$324 million (down 5% to up 1%).
Adjusted net income expected between $216 million and $232 million; adjusted EPS $6.29-$6.78 (down 2% to up 6%).
Free cash flow for 2026 projected at $100 million-$120 million; capital expenditures $95 million-$105 million (5%-6% of sales).
Latest events from Integer
- Temporary product headwinds in 2026 are expected to give way to above-market growth in 2027.ITGR
2026 KeyBanc Capital Markets Healthcare Forum18 Mar 2026 - Above-market growth is expected in 2027, driven by a robust pipeline and new product launches.ITGR
Oppenheimer 36th Annual Healthcare MedTech & Services Conference17 Mar 2026 - 2026 outlook projects flat to modest sales growth, strong pipeline, and continued capital discipline.ITGR
47th Annual Raymond James Institutional Investor Conference6 Mar 2026 - Temporary 2026 headwinds expected to give way to above-market growth in 2027 via new launches.ITGR
Citi Annual Global Healthcare Conference 20253 Feb 2026 - Targeting above-market growth and margin expansion through innovation, integration, and M&A.ITGR
2024 Truist Securities MedTech Conference3 Feb 2026 - Q2 sales up 9%, profit outlook raised, and Medical segment growth drove margin gains.ITGR
Q2 20242 Feb 2026 - Raised 2024 guidance, accelerating growth in high-value medtech markets, and strong margin expansion.ITGR
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Q3 2024 saw strong sales and profit growth, raised outlook, and strategic portfolio transformation.ITGR
Q3 202418 Jan 2026 - Growth in innovation-focused markets and successful acquisitions drive outperformance.ITGR
Piper Sandler 36th Annual Healthcare Conference12 Jan 2026